Dr William Schulyer-Jones (Associate Professor of Medicine, Duke University School of Medicine, Durham, NC, USA) shared his highlights from Virtual ACC 2021.
Speaker disclosures: Dr Schulyer-Jones has nothing to disclose in relation to this video.
Interview and filming supported by Touch Medical Media. Interview conducted by Nicola Cartridge.
Filmed during a remote video call with Dr Schulyer-Jones as a highlight of ACC 2021, May 2021.
Trending Topic
New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR
In this interview, Dr Valentina Kutyifa, University of Rochester Medical Center, Rochester, NY, USA, offers insight into the BIO LIBRA study (ClinicalTrials.gov identifier: NCT03884608), a landmark trial designed to reassess outcomes in patients with non-ischaemic cardiomyopathy in the era of contemporary medical therapy. Recognizing that much of the original evidence supporting implantable cardioverter-defibrillator (ICD) use in this population dates back decades, the BIO LIBRA study was initiated to fill key knowledge gaps using modern treatment protocols.
In this interview, Dr Louise Olde Nordkamp, a device cardiologist at Amsterdam University Medical Center, discusses the long-term findings of the PRAETORIAN XL trial—a follow-up study comparing transvenous and subcutaneous implantable cardioverter-defibrillators (ICDs). Building on the original PRAETORIAN trial, this extended 8-year analysis evaluated device-related complications and confirmed that subcutaneous ICDs carry fewer major and lead-related complications. Dr Olde Nordkamp highlights the clinical relevance of these results, supporting broader consideration of subcutaneous ICDs in patients without pacing indications.
Acute coronary syndromes (ACS) take center stage in this timely interview with Professor Sunil Rao of NYU Grossman School of Medicine and NYU Langone Health System, New York, NY, USA, as he delves into the driving forces behind the much-anticipated 2025 updates to the ACS management guidelines presented at ACC.25, Chicago, IL, USA, 29–31 March 2025.
touchCARDIO coverage of data presented at ESC 2024 touchCARDIO spoke with Dr Demilade Adedinsewo, non-invasive cardiologist at Mayo Clinic, Jacksonville, FL, USA to discuss artificial intelligence-enabled obstetric cardiovascular screening in the SPEC-AI Nigeria randomized clinical trial (ClinicalTrials.gov identifier: NCT05438576). The ...
touchCARDIO spoke with Dr Mike Gibson, Harvard Medical School, Boston, MA, USA to discuss the results of his trial investigating the relationship between apolipoprotein A-I infusions and cardiovascular outcomes, presented at ESC 2024. He explains that while high-density lipoprotein (HDL) is generally associated with good outcomes, not all HDL is equally effective at removing cholesterol from plaque, a process known as cholesterol efflux, which is crucial for better outcomes after a heart attack.
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New ...
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr ...
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with ...
CLEAR OUTCOMES trial investigated bempedoic acid and cardiovascular outcomes in statin intolerant patients with high cardiovascular risk. Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) addresses the findings, and what the implications are for clinical practice and patient care in ...
The Yellow III study aimed to assess the effect of evolocumab in combination with statins on plaque morphology in patients with stable coronary artery disease. In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai ...
Evolocumab is a proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9 inhibitor). When used in combination with statins, reduced plaque volume has been observed in patients with acute coronary syndrome (ACS). In this touchCARDIO interview, we speak with Dr Annapoorna Kini (...
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy's and St Thomas' NHS Foundation Trust, London, ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
